Prognostic factors for histiocytic and dendritic cell neoplasms

SUPPLEMENTARY MATERIALS

HS	46	11	6	5	3	2
LCS	7	3	0	0	0	0
LCH	11	7	5	3	0	0
FDCS	10	5	4	4	2	0
IDCS	5	3	2	0	0	0

Supplementary Figure 1: Overall survival for each subtype: histiocytic sarcoma (HS), Langerhans cell histiocytosis (LCH), Langerhans cell sarcoma (LCS), follicular dendritic cell sarcoma (FDCS), and interdigitating cell sarcoma (IDCS). The 2-year OS rates were 34.3% for HS, 100% for LCH, 35.2% for LCS, 60.0% for FDCS, and 75.0% for IDCS.

Supplementary Table 1: Comparison between our study and previous reports of Histiocytic sarcoma

	Our study N = 50	Previous reports[*] N = 58
Age: median [range]	68 [21-88]	56 [0.5-89]
Sex: Male/Female	1/1	1.4/1
Clinical presentation		
Nodal lesion only	31.8% (14/44)	11.8% (4/34)
Extranodal lesion only	27.3% (12/44)	44.1% (15/34)
Nodal and extranodal lesion	40.9% (18/44)	44.1% (15/34)
Laboratory data		
Albumin ≤ 3.5 g/dl	52.5% (21/40)	NA
Elevated LDH level	54.5% (24/44)	NA
Elevated CRP level	55.3% (21/38)	NA
Clinical status		
ECOG performance status 2-4	42.2% (19/45)	NA
B symptoms	31.1% (14/45)	50.0% (6/12)
Ann Arbor Stage III-IV	68.9% (31/45)	47.8% (22/46)
Therapy		
Chemotherapy	18	23
Radiation therapy	4	4
Curative operation	8	13
Chemotherapy+ radiation therapy	4	3
Chemotherapy+ operation	1	2
Radiation therapy+ operation	0	0
No therapy	11	4
Follow up periods (months)	7 (0.1-119)	26 (0.1-221)
Dead due to disease	58.7% (27/46)	45.2% (19/42)

[*]Previous reports: *Cancers (Basel)* 2014; 6: 2275-95 (Ref. 4); *Mod Pathol* 2005; 18: 693-704 (Ref 6); *Histopathology* 2002; 41: 1-29 (Ref 19); *Am J Surg Pathol* 2004; 28: 1133-44 (Ref 20), and *Eur J Cancer* 2015; 51: 2413-22 (Ref 21).
LDH, Lactate dehydrogenase: CRP, C-reactive protein: NA, Not available

Supplementary Table 2: Primer sets used for sequencing analyses for BRAF mutation in our study

Primer	Sequence (5'-3')
BRAF-Forward- first step PCR	CATAATGCTTGCTCTGATAGGAAAATGAG
BRAF Reverse- first step PCR	AACTCAGCCAGCATCTCAGGGCCAA
BRAF-Forward - second step PCR	CCTTTACTTACTACACCTCAGATATATTC
BRAF Reverse- second step PCR	GGAAAAATAGCCTCAATTCTTACCATCCAC